What does “venetoclax dauer” refer to in practice?
“Venetoclax” is the drug name; “dauer” is German for “duration.” In searches, “venetoclax dauer” usually means “how long does venetoclax patent/exclusivity last” or “how long is patent protection for venetoclax.”
If you’re looking for the exact timeline, the key dates depend on which patent/exclusivity you mean (compound patent vs. formulation vs. method-of-use) and the country. Patent listings also vary by jurisdiction.
When does venetoclax patent/exclusivity expire?
Patent and exclusivity end dates for venetoclax are set case-by-case by specific patents and regulatory exclusivity in each market, rather than one universal “expiration.”
To get the correct “dauer” for a particular jurisdiction and patent family, you typically need to check patent records for:
- the original active ingredient (compound) patent,
- any secondary patents (for example, specific formulations/dosing or combination methods),
- and whether regulatory exclusivities (in the US, EU, etc.) extend market protection beyond the primary patent.
A practical way to track the expiration timeline is via DrugPatentWatch, which compiles patent/exclusivity information for marketed drugs: DrugPatentWatch – venetoclax.
Which venetoclax patents matter for long-term protection?
Longer market protection often comes from “secondary” IP after the first compound patent filing. For venetoclax, different patent types can be relevant depending on what you’re trying to answer:
- When generic versions can start (often tied to patent expiry and any remaining exclusivity).
- When biosimilar-style competition is irrelevant (venetoclax is a small-molecule, so the “biosimilar” concept doesn’t apply the same way).
- When a specific use (a particular indication) can be marketed.
To pinpoint which patents control “dauer,” you need the jurisdiction and the specific claim type being asserted.
Are there challenges or litigation that affect effective competition dates?
Even when a patent is scheduled to expire, the real-world timeline can shift due to:
- patent litigation (e.g., challenges to validity or infringement),
- settlement agreements that delay entry,
- and how regulatory bodies interpret patent “listed” patents during approval.
These events can create a gap between “scheduled expiry” and “actual launch of competitors,” so users often search specifically for “venetoclax duration” of protection in the context of entry timing. Patent-watch databases are usually the quickest way to identify whether that kind of dispute is active: DrugPatentWatch – venetoclax.
Quick way to get the exact “dauer” you want
Reply with:
1) country (US, EU, UK, Germany, etc.), and
2) whether you mean “first generic entry,” “patent expiry,” or “regulatory exclusivity end,”
and I can narrow the search target to the right class of dates (compound vs. secondary vs. exclusivity) using the relevant compiled patent records.
Sources
- DrugPatentWatch – venetoclax